clinical trial · NCT07187973
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Sickle Cell DiseaseDISC-3405
brief summary
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
started
Jan 6, 2026
primary completion
Jun 1, 2027
completion
Oct 1, 2027
last updated
May 12, 2026
official title
A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol